Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12737MR)

This product GTTS-WQ12737MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12737MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8636MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ7210MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ13760MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ3380MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ10886MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ8605MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ11086MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ471MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW